P53 expression correlates with low axillary tumor burden in breast cancer

• Published in: Breast disease Vol. 42; no. 1; pp. 429 - 435
• Main Authors: Nicolau, Pau, Masó, Paula, Argudo, Núria, Jiménez, Marta, Martínez, Ana Isabel, Vázquez, Ivonne, Comerma, Laura, Vernet-Tomás, Maria
• Format: Journal Article
• Language: English
• Published: Netherlands 18.12.2023
• Subjects: Breast Neoplasms - pathology; Female; Humans; Immunohistochemistry; Prognosis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Tumor Burden; Tumor Suppressor Protein p53 - genetics; breast cancer; axillary tumor burden; immunophenotypes; p53
• ISSN: 0888-6008; 1558-1551
• DOI: 10.3233/BD-230013

The p53 mutation in breast cancer confers a worse prognosis and is usually associated with p53 overexpression (p53+) on immunohistochemistry. Previous studies have shown that p53+ tumors could be associated with low axillary tumor burden (ATB). We aimed to evaluate the association between p53+ and ATB in a large series of breast cancers as an aid to personalizing axillary surgical treatment. We retrieved 1762 infiltrating breast carcinomas from our database that were treated with upfront surgery in Hospital del Mar from 2004 to 2018. We compared p53+ and p53-negative (p53-) tumors in terms of the percentage of cases with high ATB and overall survival. This comparison was made overall and for each immunophenotype. Overall, 18.7% of breast tumors were p53+. High ATB was less common in p53+ tumors than in p53- tumors in the luminal B-Her2-negative immunophenotype (6.2% versus 16.9%, respectively, P = 0.025), but not in the other immunophenotypes or overall. Overall survival was worse in patients with p53+ breast cancer (P = 0.002). p53+ breast cancers were associated with worse overall survival. However, low ATB was more common in these tumors than in p53- tumors in the luminal B-Her2-negative subtype. Information on p53 expression could be of use to predict ATB in some breast cancer tumors.